Palisade Bio (PALI)
(Delayed Data from NSDQ)
$0.86 USD
-0.06 (-6.73%)
Updated Sep 30, 2025 04:00 PM ET
After-Market: $0.84 -0.02 (-2.29%) 6:30 PM ET
4-Sell of 5 4
F Value B Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PALI 0.86 -0.06(-6.73%)
Will PALI be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PALI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PALI
Palisade Bio (PALI) Upgraded to Buy: What Does It Mean for the Stock?
PALI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PALI
Is PALI poised for a decline? 200 Day Moving Average Resistance shows up after gaining 2.62%
Palisade Bio files to sell 147.1M shares of common stock
Palisade Bio files to sell 147.1M shares of common stock
Is PALI ready to move higher? Crossed Above 50 Day Moving Average shows up after rocketing 16.2%
PALI forms Stochastic Reached Overbought on September 25